Analisis Efektivitas Biaya Terapi Antidiabetes: Implikasi terhadap Rasionalisasi Pembiayaan Obat (Literature Review)
DOI:
https://doi.org/10.59841/jumkes.v4i1.3595Keywords:
Antidiabetes, Cost effectiveness analysis, Diabetes melitus tipe 2, Farmakoekonomi, Literature reviewAbstract
Diabetes melitus tipe 2 (DMT2) merupakan salah satu masalah kesehatan global dengan beban ekonomi dan klinis yang sangat tinggi. Beragam pilihan terapi antidiabetes telah tersedia, mulai dari obat konvensional seperti metformin dan sulfonilurea hingga obat generasi baru seperti inhibitor dipeptidyl peptidase-4 (DPP-4i), agonis reseptor glucagon-like peptide-1 (GLP-1 RA), dan inhibitor sodium-glucose co-transporter 2 (SGLT2i). Perbedaan harga dan efektivitas terapi menuntut adanya kajian farmakoekonomi, khususnya cost-effectiveness analysis (CEA), untuk mendukung pengambilan keputusan klinis dan kebijakan kesehatan. Literature review ini bertujuan untuk merangkum bukti CEA pada berbagai obat antidiabetes yang dipublikasikan dalam lima tahun terakhir, baik di Indonesia maupun internasional. Hasil telaah menunjukkan bahwa obat generasi baru umumnya memberikan manfaat klinis yang lebih baik, terutama dalam pencegahan komplikasi kardiorenal, namun biaya yang lebih tinggi sering menjadi kendala dalam penilaian efektivitas biaya. Sementara itu, obat konvensional tetap menjadi terapi yang relatif cost-effective pada banyak konteks, terutama di negara berpendapatan menengah. Perbedaan hasil antarstudi sangat dipengaruhi oleh harga obat, perspektif analisis, serta asumsi manfaat jangka panjang. Kajian ini menegaskan pentingnya evaluasi farmakoekonomi dalam menentukan pilihan terapi yang rasional dan efisien untuk pasien DMT2.
References
Adnan, Y., Hadju, V., Mallongi, A., & Ali, M. S. S. (2025). The economic cost of type 2 diabetes in Indonesia: A systematic review. Iranian Journal of Public Health, 54(10), 2139-2150.https://doi.org/10.18502/ijph.v54i10.20118
Al-Jedai, A. H., Almudaiheem, H. Y., Alissa, D. A., Al-Enazy, H. S., Korayem, G. B., Alghamdi, A. dan Alghamdi, S. (2022). Cost of cardiovascular disease and renal complications in patients with type 2 diabetes mellitus: A retrospective claims database analysis. PLOS ONE, 17(10), hal. e0273836. doi: 10.1371/journal.pone.0273836.
Amnan, Maharani, B. F., & Khasana, H. S. (2024). Cost-Effectiveness Analysis Terapi Antidiabetik Kombinasi Obat Oral dengan Insulin Terhadap Penyakit Diabetes Melitus Tipe II. Empiricism Journal, 5(2), 573–582.
Feng, Z., Tong, W. K., Zhang, X., & Tang, Z. (2023). Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China. Frontiers in Pharmacology, 14, 1–9. https://doi.org/10.3389/fphar.2023.1226778
Igarashi, A., Maruyama-Sakurai, K., Kubota, A., Akiyama, H., Yajima, T., Kohsaka, S., & Miyata, H. (2022). Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium–Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan. Diabetes Therapy, 13(7), 1367–1381. https://doi.org/10.1007/s13300-022-01270-8
Igarashi, A., Tachimori, H., Maruyama-Sakurai, K., Segawa, Y., Takagi, H., Akiyama, H., Imai, N., Kohsaka, S., & Miyata, H. (2025). Cost-Effectiveness Analysis of SGLT2 Inhibitors for Cardio-Renal-Metabolic Disease Based on Data from Japanese Studies. Advances in Therapy, 42(6), 2888–2905. https://doi.org/10.1007/s12325-025-03157-z
International Diabetes Federation. (2024). IDF Annual Report 2023. https://idf.org/media/uploads/2024/06/IDF-Annual-Report-2023.pdf
International Diabetes Federation. (2025). IDF Diabetes Atlas (11th ed.). https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/
Khan, M. A. B., Hashim, M. J., King, J. K., Govender, R. D., Mustafa, H., & Al Kaabi, J. (2020). Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends. Journal of Epidemiology and Global Health, 10(1), 107–111. https://doi.org/10.2991/jegh.k.191028.001
Laursen, H. V. B., Jørgensen, E. P., Vestergaard, P., & Ehlers, L. H. (2023). A systematic review of cost-effectiveness studies of newer non-insulin antidiabetic drugs: Trends in decision-analytical models for modelling of type 2 diabetes mellitus. PharmacoEconomics, 41(12), 1469–1514. https://doi.org/10.1007/s40273-023-01268-5
Li, X., Hoogenveen, R., El Alili, M., Knies, S., Wang, J., Beulens, J. W. J., Elders, P. J. M., Nijpels, G., van Giessen, A., & Feenstra, T. L. (2023). Cost-effectiveness of SGLT2 inhibitors in a real-world population: a MICADO model-based analysis using routine data from a GP registry. PharmacoEconomics, 41(10), 1249-1262. https://doi.org/10.1007/s40273-023-01286-3
Lin, W. Q., Cai, Z. J., Chen, T., Liu, M. B., Li, N., & Zheng, B. (2021). Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China. Frontiers in Endocrinology, 12(August), 1–9. https://doi.org/10.3389/fendo.2021.684960
Liu, G., Huang, Z., & Xin, Q. (2021). Cost-Effectiveness of Oral Antidiabetic Drugs: A Prospective Multicenter Study of Real-World Patients. Evidence-based Complementary and Alternative Medicine, 2021. https://doi.org/10.1155/2021/9972386
Lubis, M. A., & Suprianto, S. (2020). Analisis Cost-Effectivenees penggunaan Antidiabetik Oral pada Pasien Diabetes Melitus Tipe 2 Rawat Jalan Peserta Bpjs di Rsu Haji Medan. Jurnal Dunia Farmasi, 2(3), 128–147. https://doi.org/10.33085/jdf.v2i3.4406
Maruyama-Sakurai, K., Tachimori, H., Saito, E., & Kohsaka, S. (2024). Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in the treatment of diabetic nephropathy in Japan (hal. 5546–5554). 10.1111/dom.15832
Meng, X., Liu, X., Tan, J., Sheng, Q., Zhang, D., Li, B., Zhang, J., Zhang, F., Chen, H., Cui, T., Li, M., & Zhang, S. (2023). From Xiaoke to diabetes mellitus: A review of the research progress in traditional Chinese medicine for diabetes mellitus treatment. Chinese Medicine, 18(1), 75. https://doi.org/10.1186/s13020-023-00783-z
McEwan, P., Morgan, A. R., Boyce, R., Bergenheim, K., & Gariani, K. (2020). Cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes in the West of Scotland. Diabetes, Obesity and Metabolism, 22(10), 1806-1815. https://doi.org/10.1111/dom.14101
Priyadi, A., Permana, H., Muhtadi, A., Sumiwi, S. A., Sinuraya, R. K., & Suwantika, A. A. (2021). Cost-effectiveness analysis of type 2 diabetes mellitus (T2dm) treatment in patients with complications of kidney and peripheral vascular diseases in Indonesia. Healthcare (Switzerland), 9(2), 1–9. https://doi.org/10.3390/healthcare9020211
Rahmadanita, F. F., Maulina, N., Sugihantoro, H., Muhimmah, I., & Saputra, A. F. (2022). Analisis Efektivitas Biaya Penggunaan Antidiabetik Oral pada Pasien Diabetes Melitus Rawat Jalan di RSU Haji tomi. Pharmaceutical Journal of Indonesia 2022, 8(1), 49–58. https://doi.org/10.21776/ub.pji.2022.008.01.8
Verryn, M. T., & Cleary, S. (2025). A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa. Cost Effectiveness and Resource Allocation, 23(1). https://doi.org/10.1186/s12962-025-00615-x
World Health Organization. (2024, April 5). Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes
Wu, J., Perez, A., & Sullivan, P. W. (2025). Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes. Journal of Managed Care & Specialty Pharmacy, 31(1), 1029–1039.
Zhu, J., Zhou, Y., Li, Q., & Wang, G. (2023). Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review. Advances in Therapy, 40(10), 4216–4235. https://doi.org/10.1007/s12325-023-02612-z
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Jurnal Mahasiswa Ilmu Kesehatan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
